Cyclo Therapeutics Inc
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials fo… Read more
Cyclo Therapeutics Inc (CYTH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.608x
Based on the latest financial reports, Cyclo Therapeutics Inc (CYTH) has a cash flow conversion efficiency ratio of 0.608x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.19 Million) by net assets ($-13.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cyclo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Cyclo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cyclo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bliss Properti Indonesia Tbk PT
JK:POSA
|
-0.004x |
|
Four Leaf Acquisition Corporation Class A Common Stock
NASDAQ:FORL
|
-0.074x |
|
ST Dupont
PA:DPT
|
-0.078x |
|
Rma Global Ltd
AU:RMY
|
0.273x |
|
Arrow Minerals Ltd
AU:AMD
|
-1.377x |
|
Maritime Launch Services Inc.
OTCQB:MAXQF
|
0.014x |
|
Manganese X Energy Corp
OTCQB:MNXXF
|
-0.220x |
|
VL E-Governance & IT Solutions Limited
NSE:VLEGOV
|
N/A |
Annual Cash Flow Conversion Efficiency for Cyclo Therapeutics Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of Cyclo Therapeutics Inc from 2000 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.76 Million | $-16.19 Million | -3.402x | 0.00% |
| 2023-12-31 | $4.76 Million | $-16.19 Million | -3.402x | +83.46% |
| 2022-12-31 | $734.54K | $-15.11 Million | -20.576x | -2049.04% |
| 2021-12-31 | $15.67 Million | $-15.01 Million | -0.957x | -17.19% |
| 2020-12-31 | $10.45 Million | $-8.54 Million | -0.817x | +88.39% |
| 2019-12-31 | $935.98K | $-6.59 Million | -7.040x | -119.15% |
| 2018-12-31 | $992.52K | $-3.19 Million | -3.212x | -20.17% |
| 2017-12-31 | $1.15 Million | $-3.06 Million | -2.673x | -38.24% |
| 2016-12-31 | $1.53 Million | $-2.95 Million | -1.934x | -264.09% |
| 2015-12-31 | $3.75 Million | $-1.99 Million | -0.531x | -267.73% |
| 2014-12-31 | $4.37 Million | $-631.16K | -0.144x | -146.59% |
| 2013-12-31 | $1.80 Million | $556.54K | 0.310x | +720.75% |
| 2012-12-31 | $1.55 Million | $58.50K | 0.038x | -71.04% |
| 2011-12-31 | $1.42 Million | $185.78K | 0.130x | -12.83% |
| 2010-12-31 | $1.40 Million | $209.86K | 0.150x | +66.28% |
| 2009-12-31 | $1.20 Million | $108.13K | 0.090x | +61.10% |
| 2008-12-31 | $1.16 Million | $64.74K | 0.056x | -79.43% |
| 2007-12-31 | $1.36 Million | $370.22K | 0.271x | +482.31% |
| 2006-12-31 | $560.11K | $26.11K | 0.047x | -79.08% |
| 2005-12-31 | $577.79K | $128.77K | 0.223x | -38.38% |
| 2004-12-31 | $567.95K | $205.40K | 0.362x | +215.23% |
| 2003-12-31 | $566.26K | $64.96K | 0.115x | -53.21% |
| 2002-12-31 | $196.29K | $48.13K | 0.245x | +132.14% |
| 2001-12-31 | $30.71K | $-23.43K | -0.763x | -135.28% |
| 2000-12-31 | $88.51K | $-28.70K | -0.324x | -- |